SOAT1 and rheumatoid arthritis: Considering that the JAK-STAT pathway plays a crucial role in the cytokine-mediated production of inflammatory responses elicited by RA, the JAK inhibitors, namely, baricitinib and upadacitinib, have become a promising pharmacological target for the treatment of RA [5,25-27].